X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Dextenza (dexamethasone) is a corticosteroid intracanalicular insert, that acts as a glucocorticoid receptor agonist. It is indicated for the treatment of ocular inflammation and pain following ophthalmic surgery.
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: Dextenza
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 19, 2024
Details:
Dextenza (dexamethasone), a corticosteroid intracanalicular insert, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis.
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: Dextenza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ocular Therapeutix
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2023
Details:
PH94B (fasedienol) is a pherine nasal spray that regulates the olfactory-amygdala neural circuits of fear and anxiety and attenuates the tone of the sympathetic ANS, without systemic distribution, potentiation of GABA-A or direct activity on CNS neurons in the brain.
Lead Product(s): Fasedienol
Therapeutic Area: Psychiatry/Psychology Product Name: PH94B
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2023
Details:
Dextenza (dexamethasone), a corticosteroid intracanalicular insert, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis.
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: Dextenza
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ocular Therapeutix
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
AG-73305 is a humanized, bi-specific Fc-fusion protein designed to simultaneously block VEGFs and integrins for the treatment of DME, nAMD, RVO, and other retinal diseases and contains a VEGF-trap and a disintegrin that blocks various key integrin receptors.
Lead Product(s): AG-73305
Therapeutic Area: Ophthalmology Product Name: AM305
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Allgenesis Biotherapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
Dextenza (dexamethasone), a corticosteroid, has been shown to suppress inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage and migration of inflammatory cells.
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: Dextenza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
Details:
Under the agreement, Affamed will obtain sole commercialization rights upon regulatory approval in Mainland China to Emgality (galcanezumab), a monoclonal antibody that selectively binds to calcitonin gene-related peptide (CGRP).
Lead Product(s): Galcanezumab
Therapeutic Area: Neurology Product Name: Emgality
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Eli Lilly
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 17, 2023
Details:
In pre-clinical studies, AM712 (ASKG712) demonstrated robust efficacy, good ocular pharmacokinetics, and the desired safety profile supporting clinical exploration. AM712 is a novel bispecific biologic molecule specifically designed for ocular use.
Lead Product(s): ASKG712
Therapeutic Area: Ophthalmology Product Name: AM712
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: AskGene Pharma Inc.
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2022
Details:
First Patient dosed for DEXTENZA (dexamethasone) in China, to support and accelerate registration applications for imported therapies so that more patients can use the world's leading innovative therapies for the treatment of ocular inflammation and pain post-cataract surgery.
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: DEXTENZA
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ocular Therapeutix
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
